Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Edesa Biotech Inc EDSA

Healthcare Biotechnology
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a... see more

Recent & Breaking News (NDAQ:EDSA)

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Accesswire 7 days ago

Edesa Biotech to Participate in Upcoming Investor Conferences

Accesswire April 2, 2024

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Accesswire March 21, 2024

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Accesswire March 7, 2024

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Accesswire March 4, 2024

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Accesswire February 9, 2024

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Accesswire January 4, 2024

Edesa Biotech Reports Fiscal Year 2023 Results

Accesswire December 15, 2023

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Accesswire November 20, 2023

Edesa Biotech to Present at Dermatology Drug Development Summit

Accesswire October 26, 2023

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Accesswire October 25, 2023

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Accesswire October 12, 2023

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Accesswire October 12, 2023

Edesa Biotech Announces One-for-Seven Reverse Share Split

Accesswire October 10, 2023

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Accesswire September 28, 2023

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Accesswire August 9, 2023

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Accesswire July 26, 2023

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Accesswire June 28, 2023

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Accesswire June 27, 2023

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Accesswire May 11, 2023